Mr Timo Rusack

Luebeck (Germany)

Follow

Contributor content

Presentation

Targeting an altered sphingolipid profile with consecutive lipotoxicity as therapeutic approach to calcific aortic valve disease

ESC 365 is supported by

novartis

Explore sponsored resources